Abstract
Neo-tanshinlactone (1) was isolated and synthesized for the first time and evaluated in vitro against several human cancer cell lines. Compound 1 showed significant inhibition against two ER+ human breast cancer cell lines and was 10-fold more potent and 20-fold more selective as compared to tamoxifen citrate. Compound 1 also potently inhibited an ER-, HER-2 overexpressing breast cancer cell line. Therefore, this novel compound merits further development as an anti-breast cancer drug candidate.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antineoplastic Agents, Phytogenic / chemical synthesis
-
Antineoplastic Agents, Phytogenic / isolation & purification
-
Antineoplastic Agents, Phytogenic / pharmacology*
-
Breast Neoplasms
-
Cell Line, Tumor
-
Drug Screening Assays, Antitumor
-
Female
-
Furans / chemistry
-
Furans / isolation & purification
-
Furans / pharmacology*
-
Humans
-
Pyrones / chemistry
-
Pyrones / isolation & purification
-
Pyrones / pharmacology*
-
Receptor, ErbB-2 / biosynthesis
-
Receptors, Estrogen / biosynthesis
-
Salvia miltiorrhiza*
Substances
-
Antineoplastic Agents, Phytogenic
-
Furans
-
Pyrones
-
Receptors, Estrogen
-
neotanshinlactone
-
Receptor, ErbB-2